Literature DB >> 12667420

Early chemohormonal therapy in prostate cancer: preliminary data and randomized trials.

Daniel P Petrylak1.   

Abstract

Chemotherapy was traditionally perceived to be ineffective for prostate cancer and was only administered to patients with symptomatic hormone-refractory disease. Although previous reviews have confirmed this belief, recent studies have demonstrated significant antitumor activity with chemotherapy regimens. This article highlights the preliminary results of recent studies involving chemohormonal therapy.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12667420     DOI： 10.1007/s11912-003-0114-7

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  12 in total

1.  Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy.

Authors:  M S Khil; J H Kim; L J Bricker; J C Cerny
Journal:  Cancer J Sci Am       Date:  1997 Sep-Oct

2.  Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report.

Authors:  W K Oh; D J George; D S Kaufman; K Moss; M R Smith; J P Richie; P W Kantoff
Journal:  Semin Oncol       Date:  2001-08       Impact factor: 4.929

3.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.

Authors:  A W Partin; M W Kattan; E N Subong; P C Walsh; K J Wojno; J E Oesterling; P T Scardino; J D Pearson
Journal:  JAMA       Date:  1997-05-14       Impact factor: 56.272

Review 4.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.

Authors:  M Han; A W Partin; C R Pound; J I Epstein; P C Walsh
Journal:  Urol Clin North Am       Date:  2001-08       Impact factor: 2.241

5.  Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.

Authors:  P E Clark; D M Peereboom; R Dreicer; H S Levin; S B Clark; E A Klein
Journal:  Urology       Date:  2001-02       Impact factor: 2.649

6.  Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer.

Authors:  Michael W Kattan
Journal:  Curr Opin Urol       Date:  2003-03       Impact factor: 2.309

7.  Adjuvant mitozantrone chemotherapy in advanced prostate cancer.

Authors:  J Wang; S Halford; A Rigg; R Roylance; M Lynch; J Waxman
Journal:  BJU Int       Date:  2000-10       Impact factor: 5.588

8.  Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

Authors:  D M Savarese; S Halabi; V Hars; W L Akerley; M E Taplin; P A Godley; A Hussain; E J Small; N J Vogelzang
Journal:  J Clin Oncol       Date:  2001-05-01       Impact factor: 44.544

Review 9.  Chemotherapy for advanced hormone refractory prostate cancer.

Authors:  D P Petrylak
Journal:  Urology       Date:  1999-12       Impact factor: 2.649

Review 10.  Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer.

Authors:  A Yagoda; D Petrylak
Journal:  Cancer       Date:  1993-02-01       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.